Trials / Completed
CompletedNCT03846180
Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage
Terlipressin Versus Somatostatin/Octreotide on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage (TORCH): A Retrospective Multicenter Observational Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,682 (actual)
- Sponsor
- General Hospital of Shenyang Military Region · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Terlipressin and somatostatin/octreotide are the first-line choices for the treatment of acute variceal bleeding in liver cirrhosis. Acute kidney injury can develop in patients presenting with acute variceal bleeding. On the other hand, evidence suggests that terlipressin can reverse hepatorenal syndrome. It has been hypothesized that terlipressin can protect the renal function in cirrhotic patients with acute variceal bleeding, except for control of bleeding.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Terlipressin | Continuous or intermittent intravenous infusion of terlipressin was given. |
| DRUG | Somatostatin | Continuous or intermittent intravenous infusion of somatostatin was given. |
| DRUG | Octreotide | Continuous or intermittent intravenous infusion of octreotide was given. |
Timeline
- Start date
- 2019-03-01
- Primary completion
- 2019-06-30
- Completion
- 2019-07-01
- First posted
- 2019-02-19
- Last updated
- 2019-07-05
Locations
14 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03846180. Inclusion in this directory is not an endorsement.